Establishment Labs Holdings Inc Dossier
Qualitative Analysis
Business overview
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction. The company designs, develops, manufactures, and markets an innovative portfolio of silicone gel-filled breast implants under its flagship Motiva Implants brand. Establishment Labs is recognized for introducing advanced safety and aesthetic standards, utilizing its proprietary SmoothSilk/SilkSurface surface technology to minimize foreign body responses and clinical complications. Headquartered in Alajuela, Costa Rica, where its state-of-the-art manufacturing facilities are located, the company distributes its products in over 80 countries worldwide through a combination of direct sales and medical distributors.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercial rollout of Motiva Implants in the United States following FDA PMA approval, including expanding the specialized sales force by up to 15 representatives and opening new surgeon accounts.
Expected impact: Targeting U.S. revenue to exceed 30% of total global sales in 2026, up from approximately 22% in 2025, and aiming to capture a substantial share of the U.S. breast augmentation market.
Expanding the global footprint of the company's minimally invasive platforms, Mia Femtech and Preservu0000, across direct and distributor markets.
Expected impact: Projected to generate over $35 million in minimally invasive business revenue in 2026, up from the initial guidance of $30 million.
Amending and restating the credit agreement with Oaktree Capital Management to secure a $300 million senior secured term loan facility.
Expected impact: Extends debt maturity to 2031, enhances financial flexibility, improves liquidity with a payment-in-kind (PIK) interest option saving over $5 million per quarter, and bridges the company to cash-flow positivity.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of European distributor networks in Belgium and the Netherlands to transition from a distributor model to a direct sales model, strengthening the company's direct distribution footprint in Europe.
Financial impact: Exceeded first-year performance expectations, contributing to strong direct sales growth in Europe and supporting gross margin expansion.
Strategic Partnerships
First-of-its-kind celebrity brand partnership following FDA approval of Motiva Implants to drive consumer awareness, body positivity, and brand adoption during the U.S. market launch.
Terms: Financial terms of the endorsement and marketing agreement were not publicly disclosed; marketing expenses were primarily recognized in Q2 2025.
NuSil is the single-source supplier of medical-grade long-term implantable silicone, the primary raw material for Motiva Implants. The parties are actively negotiating a long-term extension (5 years or more) focusing on co-development and exclusivity.
Terms: The existing master supply agreement is effective through December 31, 2026, with automatic one-year renewals. Pricing terms are confidential.